Taking into consideration the importance of the expression of ERs and lumican in breast cancer cell properties and tumour progression and, in addition, the fact that lumican, due to its potent anticancer effect, may be a useful novel pharmaceutical agent for cancer targeting, we evaluated its effects in breast cancer cells of different ERα/β status. The gene discussed is ESR1; the disease is neoplasm.